Tactile Systems Technology, Inc. (NASDAQ:TCMD) VP Sells $70,759.50 in Stock

Tactile Systems Technology, Inc. (NASDAQ:TCMD - Get Free Report) VP Kristie Burns sold 4,830 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $14.65, for a total value of $70,759.50. Following the completion of the transaction, the vice president now directly owns 84,008 shares in the company, valued at $1,230,717.20. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tactile Systems Technology Price Performance

NASDAQ:TCMD traded up $0.08 during trading hours on Friday, hitting $14.29. 236,510 shares of the stock traded hands, compared to its average volume of 295,235. The company has a market cap of $337.03 million, a price-to-earnings ratio of 20.41 and a beta of 1.20. Tactile Systems Technology, Inc. has a 1 year low of $11.12 and a 1 year high of $21.10. The stock has a 50 day moving average price of $17.03 and a 200 day moving average price of $15.71. The company has a quick ratio of 3.80, a current ratio of 4.36 and a debt-to-equity ratio of 0.11.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.09. The company had revenue of $85.59 million for the quarter, compared to analysts' expectations of $85.39 million. Tactile Systems Technology had a net margin of 5.79% and a return on equity of 9.37%. Sell-side analysts forecast that Tactile Systems Technology, Inc. will post 0.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TCMD has been the topic of several recent research reports. BTIG Research downgraded shares of Tactile Systems Technology from a "buy" rating to a "neutral" rating in a research report on Tuesday, November 5th. Oppenheimer lowered Tactile Systems Technology from an "outperform" rating to a "market perform" rating in a research note on Tuesday, November 5th. B. Riley downgraded Tactile Systems Technology from a "buy" rating to a "neutral" rating and lowered their target price for the company from $23.00 to $18.00 in a research report on Wednesday, February 19th. Finally, StockNews.com lowered Tactile Systems Technology from a "strong-buy" rating to a "buy" rating in a report on Thursday, January 16th.

Hedge Funds Weigh In On Tactile Systems Technology

Several large investors have recently made changes to their positions in TCMD. FMR LLC grew its position in shares of Tactile Systems Technology by 28.1% during the third quarter. FMR LLC now owns 79,348 shares of the company's stock worth $1,159,000 after purchasing an additional 17,393 shares in the last quarter. Wasatch Advisors LP boosted its position in shares of Tactile Systems Technology by 9.8% during the third quarter. Wasatch Advisors LP now owns 727,194 shares of the company's stock worth $10,624,000 after acquiring an additional 64,684 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in Tactile Systems Technology during the fourth quarter valued at $1,328,000. Geode Capital Management LLC increased its holdings in Tactile Systems Technology by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 558,667 shares of the company's stock valued at $8,164,000 after acquiring an additional 8,422 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Tactile Systems Technology by 16.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 45,374 shares of the company's stock valued at $663,000 after acquiring an additional 6,401 shares during the last quarter. 83.43% of the stock is currently owned by hedge funds and other institutional investors.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.